Show Summary Details
Page of

Multiple System Atrophy (MSA) 

Multiple System Atrophy (MSA)
Multiple System Atrophy (MSA)

Gregor K. Wenning

and Florian Krismer

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 October 2021

Multiple system atrophy (MSA) is an adult-onset atypical parkinsonian disorder (APD) characterized by either rapidly progressive levodopa-unresponsive parkinsonism or a cerebellar syndrome associated with early autonomic failure. According to current consensus criteria two motor subtypes can be distinguished clinically, namely a parkinsonian variant labelled MSA-P and a cerebellar variant labelled MSA-C . Abundant (oligodendro-)glial cytoplasmic inclusions (GCI) represent the histopathological signature lesion that is accompanied by a selective neuronal multisystem degeneration. The principle component of GCIs is α-synuclein, a finding which firmly places MSA among other α-synucleinopathies such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Currently, the management of MSA patients is based on symptomatic treatment targeting parkinsonian and autonomic features. Although research into disease-modifying strategies has accelerated, effective neuroprotective treatments are still lacking.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.